Latest news and press releases about Neonc Technologies Holdings, Inc. (NTHI): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
NeOnc Technologies Holdings, Inc. is a clinical-stage biopharmaceutical company. It develops novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. The company was founded in 2008 and is headquartered in Calabasas, CA.
Price
| Price | $2.99 |
| Market Cap | $78M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | -4.25 |
| EV / EBITDA | -2.95 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | 309.09% |
| Return on Invested Capital | 229.42% |
| Return on Assets | -902.18% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Explore sector: Healthcare · Biotechnology
More sections of NTHI: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks